business
Simcere Pharmaceutical Signs Research Deal with Stanford Medicine on Lung Disease Therapy
Simcere Pharmaceutical Group Limited entered a collaboration agreement with Stanford Medicine on May 29, 2026, to fund early-stage research on a potential treatment for idiopathic pulmonary fibrosis. The company will provide funding and, if the study succeeds, will license the molecule and hold global rights to any resulting product.
Jun 12, 2:59 AM·1m read2 sources
forbes.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Simcere Pharmaceutical Group Limited entered into a research collaboration agreement with Stanford Medicine on May 29, 2026, to fund an exploratory study aimed at developing a therapy for idiopathic pulmonary fibrosis. Under the agreement, Simcere will finance the initial research on a first-in-class molecule.
If the study meets its objectives, Simcere will in-license the molecule and receive 100 percent of the global rights to any resulting product. The work will take place at Stanford Medicine laboratories affiliated with the Stanford Innovative Medicines Accelerator.
Background on the Agreement Idiopathic pulmonary fibrosis is a progressive lung disease with limited treatment options. The collaboration focuses on early-stage discovery rather than clinical development. The agreement does not include financial terms or a timeline for potential product development.
Transparency
How sources framed this
These outlets didn't split into competing frames — coverage was uniform.
CorroborationLimited · 2 sources
